



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DAT	E FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/627,920	07/28/200	Nils Ove Gustavsson	003301-072	3614	
21839	7590 08/	11/2004	EXAM	EXAMINER	
BURNS DO	ANE SWECKI	KRISHNAN,	KRISHNAN, GANAPATHY		
POST OFFICE BOX 1404 ALEXANDRIA, VA 22313-1404			ART UNIT	PAPER NUMBER	
ALLAANDK	IA, VA 22313	1 10 1	1623		

DATE MAILED: 08/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	n No.	Applicant(s)				
		10/627,920)	GUSTAVSSON ET AL.				
	Office Action Summary	Examiner		Art Unit				
		Ganapathy		1623				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).								
Status								
1)	Responsive to communication(s) filed	on						
,	This action is FINAL . 2b) This action is non-final.							
,	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
 4) Claim(s) 30-34 and 36-47 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) is/are allowed. 6) Claim(s) 30-34 and 36-47 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or election requirement. 								
Applicati	on Papers							
,	The specification is objected to by the		_					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.								
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority under 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 09/970,648. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 								
2) Notice 3) Inform	t(s) se of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTo- mation Disclosure Statement(s) (PTO-1449 or Pier No(s)/Mail Date		4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informat P 6) Other:	·				

Art Unit: 1623

DETAILED ACTION

Specification

The disclosure is objected to because of the following informalities: At the top of the page where the claims begin the terms "We Claim" should replace "Listing of Claims".

Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 31, 33-34 and 36-46 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 31(c) recites, "lacks covalently bonded additional chemical groups of the type that occur in hydroxyethyl starch". This recitation does not clearly point out which groups are excluded. It is not clear what is intended. Clarification is needed.

Claims 33 and 38 recite the term especially. This recitation renders the claims indefinite since it is unclear whether the limitation(s) following the phrase are part of the claimed invention.

Claims that depend from rejected base claims that are unclear/indefinite are also rendered unclear/indefinite.

Application/Control Number: 10/627,920

Art Unit: 1623

Double Patenting

A rejection based on double patenting of the "same invention" type finds its support in the language of 35 U.S.C. 101 which states that "whoever invents or discovers any new and useful process ... may obtain a patent therefor ..." (Emphasis added). Thus, the term "same invention," in this context, means an invention drawn to identical subject matter. See *Miller v. Eagle Mfg. Co.*, 151 U.S. 186 (1894); *In re Ockert*, 245 F.2d 467, 114 USPQ 330 (CCPA 1957); and *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970).

A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the conflicting claims so they are no longer coextensive in scope. The filing of a terminal disclaimer <u>cannot</u> overcome a double patenting rejection based upon 35 U.S.C. 101.

Claims 30-32, 34, 46 and 47 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 29-34, 36-41, 46 and 47 of copending Application No. 10/461,393 ('393).

Claims 30-32, 34, 46 and 47 are drawn to pharmaceutically acceptable starch with limitations that are also seen in claims 29-34, 36-41, 46 and 47 of the copending '393 application.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Art Unit: 1623

Claims 30, 31, 36 and 42-45 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 17-19 of U.S. Patent No. 6,692,770 ('770 patent). Although the conflicting claims are not identical, they are not patentably distinct from each other because:

Claims 30, 31, 36 and 42-45 are drawn to a starch with limitations drawn to percentage of amylopectin, the percentage of amylopectin having a molecular weight in the range 10-10000 kDa, nitrogen content, microparticles of starch, size of the said microparticles, ability to be dissolved by enzyme action in vitro or elimination from biological tissue.

These same limitations are also seen in claims 1 and 17-19 of the '770 patent.

A patentable distinction is not seen between the microparticles starch of the '770 patent and the starch of the instant claims.

It would have been obvious to one of ordinary skill in the art that the starch of the instant application and that of the copending '770 patent are substantially the same. The starch of claims 30, 31, 36 and 42-45 of the instant application should recite limitations that would make it patentably distinct from the starch of the '770 patent.

This is a <u>provisional</u> double patenting rejection since the conflicting claims have not in fact been patented.

Conclusion

Claims 30-34 and 36-47 are rejected.

Application/Control Number: 10/627,920

Art Unit: 1623

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ganapathy Krishnan whose telephone number is 571-272-0654. The examiner can normally be reached on 8.30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

GK

JAMES O. WILSON

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600